Pricing:
Members: Complimentary
Non-Members: $25
Description:
Prescription drugs are essential to modern health care. However, access to and affordability of drugs continue to be critical problems for both providers and patients. Access to drugs has been challenged by drug quality issues, product recalls, disrupted supply chains, and drug shortages. Affordability of needed prescription drugs is a function of both growing drug prices and changing insurance coverage. New players such as Amazon, Good Rx, SPARC, Civica, and others have entered the pharmacy market claiming to address access and affordability issues. What role will old and new players serve in the evolving health care market? Will these new players improve consumer access, affordability and accountability for pharmaceuticals? How can you recognize access and affordability issues in your own patients and what can you do to help them?
Learning Objectives:
- Explore the role of disruptive pharmacy players such as Amazon, Good Rx, PBMs and others.
- Describe and discuss the objectives of these disruptive players in the pharmacy space.
- Explain the concepts of access, affordability and accountability as they apply to pharmaceuticals.
- Know how to recognize and assess drug affordability in your own patients and how to improve access through value-based drug use.
REGISTER
|
|
Stephen W. Schondelmeyer, PharmD, MPubAdm, PhD, FAPhA
Dr. Schondelmeyer is a professor in the University of Minnesota’s College of Pharmacy where he holds the Century Mortar Club Endowed Chair in Pharmaceutical Management & Economics. He serves as the Director of the PRIME Institute, which focuses on pharmaceutical research related to economic and public policy issues related to pharmaceuticals and pharmacists. For the past 2 years, Dr. Schondelmeyer has worked along with Dr. Michael Osterholm as the co-principal investigator of the Resilient Drug Supply Project (RDSP) in the University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP). The RDSP focuses on the global supply chain for all prescription drug products used in the U.S. health care market in order to reduce or avoid disruptions from any cause and for any reason. The overall goal is to predict, prevent and eliminate drug shortages in the U.S. market. Dr. Schondelmeyer served on the Minnesota Attorney General’s Advisory Task Force on Lowering Pharmaceutical Drug Prices (2019-2020) and the Minnesota Dept. of Commerce’s PBM Rulemaking Advisory Committee (2020). He was appointed to the Prescription Drug Payment Review Commission, which served in an oversight and advisory capacity to the U.S. Congress for the outpatient drug program authorized under the Medicare Catastrophic Coverage Act of 1988. He has conducted policy analysis in many areas, such as reimbursement of prescription drugs under Medicaid, Medicare, managed care and other third-party programs. He has conducted research projects for a variety of sponsors, including the Centers for Medicare & Medicaid Services (CMS), the US Government Accountability Office (GAO), the Congressional Office of Technology Assessment (OTA), the US Senate Special Committee on Aging, the Food and Drug Administration (FDA), the pharmaceutical industry, and pharmacy associations.
|
Continuing Education:
This presentation is being submitted to the Minnesota Board of Pharmacy for Continuing Education credit approval (one hour).
To receive Board of Pharmacy credits for this program, the following must be completed:
Board of Pharmacy credit processing takes place on the 15th of each month.
 |
The Minnesota Pharmacists Association is accredited by the Minnesota Board of Pharmacy as a provider of continuing pharmacy education. |
Please contact lilym@mpha.org with any technical questions or issues.
Questions? Please contact info@mpha.org with questions about credits.
|
Print Page